Literature DB >> 30106649

Real-World Data Analytics Fit for Regulatory Decision-Making.

Sebastian Schneeweiss1, Robert J Glynn1.   

Abstract

Healthcare database analyses (claims, electronic health records) have been identified by various regulatory initiatives, including the 21st Century Cures Act and Prescription Drug User Fee Act ("PDUFA"), as useful supplements to randomized clinical trials to generate evidence on the effectiveness, harm, and value of medical products in routine care. Specific applications include accelerated drug approval pathways and secondary indications for approved medical products. Such real-world data ("RWD") analyses reflect how medical products impact health outside a highly controlled research environment. A constant stream of data from the routine operation of modern healthcare systems that can be analyzed in rapid cycles enables incremental evidence development for regulatory decision-making. Key evidentiary needs by regulators include 1) monitoring of medication performance in routine care, including the effectiveness, safety and value; 2) identifying new patient strata in which a drug may have added value or unacceptable harms; and 3) monitoring targeted utilization. Four broad requirements have been proposed to enable successful regulatory decision-making based on healthcare database analyses (collectively, "MVET"): Meaningful evidence that provides relevant and context-informed evidence sufficient for interpretation, drawing conclusions, and making decisions; valid evidence that meets scientific and technical quality standards to allow causal interpretations; expedited evidence that provides incremental evidence that is synchronized with the decision-making process; and transparent evidence that is audible, reproducible, robust, and ultimately trusted by decision-makers. Evidence generation systems that satisfy MVET requirements to a high degree will contribute to effective regulatory decision-making. Rapid-cycle analytics of healthcare databases is maturing at a time when regulatory overhaul increasingly demands such evidence. Governance, regulations, and data quality are catching up as the utility of this resource is demonstrated in multiple contexts.

Entities:  

Mesh:

Year:  2018        PMID: 30106649     DOI: 10.1177/0098858818789429

Source DB:  PubMed          Journal:  Am J Law Med        ISSN: 0098-8588


  5 in total

1.  The Medicines Intelligence Centre of Research Excellence: Co-creating real-world evidence to support the evidentiary needs of Australian medicines regulators and payers.

Authors:  Nicole Pratt; Ximena Camacho; Claire Vajdic; Louisa Degenhardt; Tracey-Lea Laba; Jodie Hillen; Christopher Etherton-Beer; David Preen; Louisa Jorm; Natasha Donnolley; Alys Havard; Sallie-Anne Pearson
Journal:  Int J Popul Data Sci       Date:  2022-06-13

2.  Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes.

Authors:  Jerome Jourquin; Stephanie Birkey Reffey; Cheryl Jernigan; Mia Levy; Glendon Zinser; Kimberly Sabelko; Jennifer Pietenpol; George Sledge
Journal:  JCO Precis Oncol       Date:  2019-09-12

3.  Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.

Authors:  Mehmet Burcu; Nancy A Dreyer; Jessica M Franklin; Michael D Blum; Cathy W Critchlow; Eleanor M Perfetto; Wei Zhou
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-03-11       Impact factor: 2.890

Review 4.  Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World.

Authors:  Douglas McNair; Murray Lumpkin; Steven Kern; Daniel Hartman
Journal:  Clin Pharmacol Ther       Date:  2021-10-31       Impact factor: 6.903

Review 5.  Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go.

Authors:  Ruggero De Maria Marchiano; Gabriele Di Sante; Geny Piro; Carmine Carbone; Giampaolo Tortora; Luca Boldrini; Antonella Pietragalla; Gennaro Daniele; Maria Tredicine; Alfredo Cesario; Vincenzo Valentini; Daniela Gallo; Gabriele Babini; Marika D'Oria; Giovanni Scambia
Journal:  J Pers Med       Date:  2021-03-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.